| Field | Specification |
|---|---|
| Target | |
| Alternative names | Molybdopterin synthase catalytic subunit; MOCO1-B; Molybdenum cofactor synthesis protein 2 large subunit; Molybdenum cofactor synthesis protein 2B; MOCS2B; Molybdopterin-synthase large subunit; MPT synthase large subunit; MOCS2; MCBPE; MOCO1 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human MOCS2 recombinant protein (Position: M1-E168). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody detects molybdopterin synthase catalytic subunit (gene MOCS2) in human samples and is validated for Western blot, IHC, flow cytometry and ELISA. The predicted molecular weight is 20.9 kDa, and the supplier reports an observed band at about 21 kDa.
MOCS2 is the catalytic subunit of molybdopterin synthase, which adds two sulfur atoms to the precursor cPMP to form molybdopterin during molybdenum cofactor biosynthesis. Mutations in MOCS2 cause molybdenum cofactor deficiency.
| Target | Molybdopterin synthase catalytic subunit (gene MOCS2; UniProt O96007, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 20.9 kDa |
| Observed MW | 21 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human A549 cells, human LNCAP cells, human HeLa cells, human 293T cells, human Jurkat cells, human K562 cells, human HepG2 cells, human MCF-7 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human liver cancer tissue, human lung cancer tissue, human placenta tissue, human skeletal muscle tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with a confirmed signal (flow cytometry): Jurkat cells.
Immunogen
Recombinant human MOCS2 fragment (Met1–Glu168), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human. UniProt places molybdopterin synthase catalytic subunit in the cytoplasm and nucleus. Tissue expression noted by UniProt (human): Highest levels are found in heart and skeletal muscle. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
